BioSpace2h
Novo’s Wegovy Launched in China at a Fraction of US Price
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...
BioSpace17h
Cybin’s Small Depression Study Shows 71% Remission Rate
Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month ...
BioSpace4h
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also ...
BioSpace4h
Intellia’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
BioSpace11h
SignalChem’s Tau Proteins: Accelerating Neurodegenerative Disease Research
SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may ...
BioSpace12h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...